Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Immun ; 73(11): 7348-55, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16239533

ABSTRACT

Host defenses against the encapsulated yeast Cryptococcus neoformans involve both humoral and cell-mediated immunity. Mannoproteins (MPs) are a heterogeneous class of immunodominant glycoproteins which have been only incompletely characterized. In this study, we report on the molecular features of two novel MPs that are recognized by serum antibodies during cryptococcosis. After fractionation of extracellular cryptococcal products, MPs reacted more strongly than other components with sera from C. neoformans-infected AIDS patients. Further fractionation and Western blot analysis of MPs evidenced the presence of highly reactive bands with molecular masses of 250, 125, 115, and 84 kDa. The 115- and 84-kDa bands contained significant amounts of N-linked oligosaccharides, as shown by decreased molecular mass after peptide-N-glycosidase F treatment. N-terminal amino acid sequences of the two bands were used to search C. neoformans nucleotide databases. Homologous genomic sequences were used to synthesize DNA probes and isolate cDNA clones containing the full-length genes, which were designated MP84 and MP115. Both genes showed the presence of a serine/threonine-rich region, a potential site for heavy glycosylation. MP84 and MP115 showed homology with, respectively, polysaccharide deacetylases and carboxylesterases from other organisms. Recombinant, deglycosylated proteins expressed in Escherichia coli still reacted with sera from patients, albeit more weakly than natural MPs, indicating that at least some of the reactive epitopes were retained in the recombinant forms. In conclusion, we identified two novel MPs that are important targets of antibody responses during cryptococcosis. These data may be useful to devise alternative immunity-based strategies to control the disease.


Subject(s)
Antibodies, Fungal/immunology , Antigens, Fungal/immunology , Cryptococcus neoformans/immunology , Fungal Proteins/immunology , Immune Sera/immunology , Membrane Glycoproteins/immunology , Amino Acid Sequence , Animals , Antigens, Fungal/chemistry , Antigens, Fungal/genetics , Cloning, Molecular , Cryptococcosis/immunology , Cryptococcus neoformans/chemistry , Cryptococcus neoformans/genetics , Female , Fungal Proteins/chemistry , Fungal Proteins/genetics , Humans , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/genetics , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Sequence Homology, Amino Acid
2.
Infect Immun ; 72(1): 295-300, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14688108

ABSTRACT

Previous studies demonstrated that interleukin-12 (IL-12)-dependent gamma interferon (IFN-gamma) responses have a major role in restricting in vivo bacterial growth during infection of mice with group B streptococci (GBS), important human pathogens. Like IL-12, IL-18 is a potent IFN-gamma inducer. The role of IL-18 in experimental GBS infection was investigated here. Significant elevations of IL-18 levels over baseline values were detected in plasma samples from neonatal mice rendered septic with GBS. Neutralization of IL-18 significantly increased mortality and bacterial burden (P < 0.05). In contrast, administration of recombinant IL-18 (rIL-18) before or after GBS challenge remarkably improved survival and decreased blood colony counts, in association with increased IFN-gamma production by spleen cells. The beneficial effects of rIL-18 were counteracted by administration of neutralizing anti-IFN-gamma monoclonal antibodies, indicating that the effects of IL-18 were mediated by IFN-gamma. Finally, low rIL-18 doses that had no effect of their own on bacterial burden could act in synergy with rIL-12 to protect neonatal mice during GBS infection. Collectively, our data indicate that IL-18 responses have an important role in host defenses against GBS and that rIL-18 may be useful in alternative strategies to treat neonatal GBS disease.


Subject(s)
Bacteremia/immunology , Interleukin-18/immunology , Streptococcal Infections/immunology , Streptococcus agalactiae/immunology , Animals , Animals, Newborn , Bacteremia/microbiology , Bacteremia/prevention & control , Disease Models, Animal , Humans , Infant, Newborn , Interleukin-12/administration & dosage , Interleukin-12/genetics , Interleukin-12/immunology , Interleukin-18/administration & dosage , Interleukin-18/blood , Interleukin-18/genetics , Mice , Mice, Inbred BALB C , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Streptococcal Infections/microbiology , Streptococcal Infections/prevention & control , Streptococcus agalactiae/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...